Table 3.
Number of infants progressing to chronic Chagas disease per 10,000 infants born to Chagas-positive women [mean (95% uncertainty interval)] and their lifetime costs ($US) for various vaccination strategies (assuming the current transmission risk estimate, a distribution with a median of 5%, range 4% to 6%)
| Number of Infants that Can Progress to Chronic Disease | Number of Infants that Progress to Chronic Disease | Lifetime Third-Party Payer Cost | Lifetime Societal Cost | |
|---|---|---|---|---|
| No Vaccination | 229(145–330) | 56 (34–89) | 174,299 (103,270–279,162) |
1,610,458 (808,222–2,905,913) |
| Vaccination | ||||
| 25% efficacy | 172 (100–250) | 43 (24–67) | 131,765 (70,483–213,175) |
1,207,374 (580,993–2,212,298) |
| 50% efficacy | 115 (60–190) | 29 (14–50) | 88,231 (43,790–157,315) |
803,707 (357,043–1,627,632) |
| 75% efficacy | 57 (20–110) | 14 (5–29) | 42,847 (14,883–91,089) |
391,647 (128,841–911,751) |